Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 12,523 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Hidradenitis Suppurativa (HS)
Interventions: NAV-240, Placebo to match NAV-240; Drug
Lead sponsor: Navigator Medicines, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Maitland, Florida + 9 more

Conditions: Endometrial Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan, Cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more

Conditions: Covid19
Interventions: BNT162b2 vaccine, JNJ-78436735 Vaccine; Biological
Lead sponsor: Giselle Guerra; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole MR, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 99
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions: Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Acne Vulgaris, Acne
Interventions: CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more

Conditions: Anaemia
Interventions: 5 mg GSK1278863; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Pudendal Nerve
Interventions: Robotic Assisted Laparoscopic Prostatectomy, Application of Absorbable Hemostat, Application of dehydrated human amniotic membrane; Procedure · Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 45 Years to 70 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Child, Only
Interventions: Healthy Caregivers- Healthy children, Jump Start; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: REGN475, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 69 more

Conditions: Degenerative Disc Disease
Interventions: IDCT (rebonuputemcel), Sham (No Treatment); Biological · Other
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Poor Quality Sleep
Interventions: Cognitive Behavioral Therapy (CBT); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dravet Syndrome
Interventions: zorevunersen, Sham Comparator; Drug · Other
Lead sponsor: Stoke Therapeutics, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more

Conditions: Liver Diseases
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Miami, Florida • Miramar, Florida • Orlando, Florida + 1 more

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions: Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 482
States / cities: Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more

Conditions: Perennial Allergic Rhinitis
Interventions: GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more

Conditions: Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Not listed
Lead sponsor: Florida International University; Other
Eligibility: 1 Day to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasms, Melanoma
Interventions: Modakafusp Alfa, Pembrolizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 12 more

Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions: lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more

Search by objective public record fields.

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

COVID-19 3rd Dose Vaccine in Transplant Patients

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy

Healthy Caregivers-Healthy Children

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

Sleep Well for Healthy Brain

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)